Bibliography
- Siegel R, Naishadham D, Jemal A. Cancer Statistics 2012. CA Cancer J Clin 2012;62:10-29
- Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res 2011;17:3867-75
- Hwang C, Heath EI. Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 2010;3:26
- Aragon-Ching JB, Madan RA, Dahit WL. Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol 2010;Article ID 361836:7 pages
- Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
- Chung A, Lee J, Ferrara N. Targeting the tumor vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
- Jimenez JA, Kao C, Raikwar S, Gardner TA. Current status of anti-angiogenesis therapy for prostate cancer. Urol Oncol 2006;24:260-8
- Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012;320:130-7
- Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol 2011;55:383-8
- Bianchini D, Zivi A, Sandhu A, de Bono JS. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Expert Opin Investig Drugs 2010;19:1487-502
- Osanto S, Van Poppel H. Emerging new therapies for advanced prostate cancer. Ther Adv Urol 2012;4:3-12
- Roukos DH, Tzakos A, Zografos G. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 2009;9:1413-16
- Ribatti D. Antiangiogenic therapy accelerates tumor metastasis. Leuk Res 2011;35:24-6